Glen Newell

Head of Medical Affairs, Biogen Canada

Glen Newell has been the Head of Medical Affairs of Biogen Canada since 2020. In this role, Glen oversees all medical and scientific affairs for the Canadian affiliate of Biogen, one of the world’s leading biotechnology companies and only player exclusively focused on neuroscience.

Glen joined Biogen after successful academic and industry careers, with more than 15 years of experience in Medical & Scientific Affairs in the pharmaceutical industry. He started his industry career in early phase clinical development at Biovail Contract Research before joining Takeda Canada as a Medical Science Liaison in 2011. Since that time, Glen has held multiple strategic roles at Cubist, Merck, and Shire, and has worked across several therapeutic areas, including gastroenterology, immunology, infectious diseases, anesthesia, surgery, rheumatology, nephrology, and rare genetic diseases.

Glen earned his BSc (Hon. Biology) from Acadia University in Nova Scotia, and his PhD in Pharmacology from the University of Alberta. He later completed post-doctoral fellowships in neurophysiology at the University of Wisconsin-Madison, and subsequently in anesthesiology at the University of Toronto.

Glen’s research has been published in leading academic journals. His research interests include the structure and function of ligand-gated ion channels, notably GABA-A receptors, and their allosteric modulation by various classes of therapeutic agents (e.g., benzodiazepines, barbiturates, general anesthetics, etc). Throughout his academic career, Glen’s research was supported by the Canadian Institutes of Health Research (CIHR), Neuroscience Canada Foundation (now Brain Canada), Alberta Heritage Fund for Medical Research (AHFMR) and the Natural Sciences and Engineering Research Council (NSERC).